Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Want to cut your energy bills? Here’s how five experts are doing it 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Dublin, May 30, 2017 -- Research and Markets has announced the addition of the "Osteoporosis Market and Forecast Analysis" report to their offering.
Osteoporosis is the most common metabolic bone disorder, and is characterized by low bone mass accompanied by microarchitectural deterioration of bone tissue. The consequent increase in bone fragility results in osteoporosis patients being prone to sustaining fractures. Although the majority of osteoporosis patients are postmenopausal women, it is not a female-only disease.
It is estimated that one in three women and one in five men aged over 50 years will sustain an osteoporosis-related fracture, and the associated complications represent a huge socioeconomic burden. Treatment of osteoporosis can be a challenge as bone loss is essentially symptomless until a fracture occurs, which can lead to difficulties with diagnosis and patient compliance.
Key Topics Covered:
1. EPIDEMIOLOGY: OSTEOPOROSIS
- Executive Summary
- Disease Background
- Sources and Methodology
- Forecast: Osteopenia
- Forecast: Osteoporosis
- Epidemiologist Insight
- Strengths and Limitations
- Appendix: Additional Sources
2. MARKETED DRUGS: OSTEOPOROSIS
- Product Overview
- Bisphosphonates
- Estrogens and SERMs
- Calcitonin
- Other Drug Classes
- Product profile: Forteo
- Product profile: Prolia
3. PIPELINE: OSTEOPOROSIS
- Clinical Pipeline Overview
- Comparator Therapy
- Recently Discontinued Drugs
- Product profile (late stage): Evenity
- Product profile (late stage): abaloparatide
For more information about this report visit http://www.researchandmarkets.com/research/8qtmv3/osteoporosis
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Endocrine and Metabolic Disorders Drugs, Musculoskeletal Disorders Drugs
